Steven James Net Worth

The estimated Net Worth of Steven P James is at least $433 millier dollars as of 28 September 2021. Mr. James owns over 4,000 units of Allakos Inc stock worth over $2,440 and over the last 21 years he sold ALLK stock worth over $0. In addition, he makes $430,760 as Independent Director at Allakos Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. James ALLK stock SEC Form 4 insiders trading

Steven has made over 6 trades of the Allakos Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 4,000 units of ALLK stock worth $2,120 on 28 September 2021.

The largest trade he's ever made was exercising 9,058 units of Allakos Inc stock on 24 June 2017 worth over $5,525. On average, Steven trades about 1,355 units every 87 days since 2003. As of 28 September 2021 he still owns at least 4,000 units of Allakos Inc stock.

You can see the complete history of Mr. James stock trades at the bottom of the page.

Steven James biography

Steven P. James serves as Independent Director of the Company. From July 2014 to present, Mr. James has been an independent director at several biotechnology companies and served as acting or interim Chief Executive Officer at Antiva Biosciences (previously Hera Therapeutics) and Pionyr Immunotherapeutics (previously Precision Immune). Mr. James served as President and Chief Executive Officer of Labrys Biologics, from December 2012 until its acquisition by Teva Pharmaceuticals in July 2014. He was President and Chief Executive Officer of KAI Pharmaceuticals, from October 2004 until its acquisition by Amgen in July 2012. He was Senior Vice President, Commercial Operations, at Exelixis, from 2003 until 2004. Previously he held senior business roles at Sunesis Pharmaceuticals and Isis Pharmaceuticals. He began his career in new product planning at Eli Lilly and Company. Mr. James was also a member of the board of directors of Cascadian Therapeutics and Ocera Therapeutics, and is currently a director of Antiva Biosciences and Pionyr Immunotherapeutics, where he has been President and Chief Executive Officer since January 2016. Mr. James earned a Bachelor of Arts degree in biology from Brown University and a Masters in Management degree from the Kellogg Graduate School of Management at Northwestern University

What is the salary of Steven James?

As the Independent Director of Allakos Inc, the total compensation of Steven James at Allakos Inc is $430,760. There are 13 executives at Allakos Inc getting paid more, with Robert Alexander having the highest compensation of $12,559,300.

How old is Steven James?

Steven James is 62, he's been the Independent Director of Allakos Inc since 2016. There are no older and 9 younger executives at Allakos Inc.

What's Steven James's mailing address?

Steven's mailing address filed with the SEC is C/O ALLAKOS INC., 825 INDUSTRIAL ROAD, SUITE 500, SAN CARLOS, CA, 94070.

Insiders trading at Allakos Inc

Over the last 6 years, insiders at Allakos Inc have traded over $246,100,922 worth of Allakos Inc stock and bought 5,181,222 units worth $35,384,176 . The most active insiders traders include Paul Edward Walker, Group, Llc Green Jeremy Red... et Daniel Janney. On average, Allakos Inc executives and independent directors trade stock every 43 days with the average trade being worth of $114,372. The most recent stock trade was executed by Harlan Baird Radford on 28 June 2024, trading 87,064 units of ALLK stock currently worth $87,935.

What does Allakos Inc do?

allakos inc is a biotechnology company located in 7400 paseo padre pkwy, fremont, ca, united states.

Complete history of Mr. James stock trades at Exelixis Inc et Allakos Inc

Allakos Inc executives and stock owners

Allakos Inc executives and other stock owners filed with the SEC include:

• Robert Alexander,
  Chief Executive Officer, Director
• Adam Tomasi,
  President, Chief Operating Officer
• Henrik Rasmussen,
  Chief Medical Officer
• Leo Redmond,
  Chief Financial Officer
• Mark Asbury,
  Chief Legal Officer and General Counsel
• Dr. Robert Alexander Ph.D.,
  CEO & Director
• Dr. Adam L. Tomasi Ph.D.,
  Pres & COO
• Dr. Henrik Sandvad Rasmussen,
  Strategic Advisor
• Mark Asbury,
  Chief Legal Officer & Gen. Counsel
• Daniel Janney,
  Independent Chair of the Board
• Robert Andreatta,
  Independent Director
• John McKearn,
  Independent Director
• Paul Walker,
  Independent Director
• Steven James,
  Independent Director
• Dr. Craig Paterson M.D.,
  Chief Medical Officer
• Alan Chang,
  Director of Medical Affairs & Data Analytics
• Tim Varacek,
  Chief Commercial Officer
• Dr. Sally D. Bolmer,
  Sr. VP of Regulatory Affairs & Drug Devel.
• Dr. Ruby Casareno Ph.D.,
  Sr. VP of Technical Operations
• Baird Radford III,
  Chief Financial Officer
• Group, Llc Green Jeremy Red...,
  
• Venture Fund Iii, L.P.River...,
  
• Partners Viii, L.P.Alta Par...,
  
• Neil Murray Hamilton Graham,
  
• Amy L Ladd,
  
• Dolca Thomas,
  
• Partners Next Gen Fund I Ma...,
  
• Peter A Hudson,
  
• Robert J More,
  
• Guy P Nohra,
  10% owner
• Natalie C. Holles,
  Director
• Partners Next Gen Fund I Ma...,
  
• Margaret Nell Fitzgerald,
  General Counsel and Secretary
• Craig A. Paterson,
  Chief Medical Officer
• Everett Rand Sutherland,
  Director
• Partners Management Viii, L...,
  
• Chin Hyok Lee,
  Chief Medical Officer
• Harlan Baird Radford,
  Chief Financial Officer